Clinical Trial Search

Primary: Assessment of DENV, ZIKV, CHIKV Seroprevalence Via Screening PRNT50 Titers in Cambodian Adults. — 300 Participants

Primary: AEs Grade 3 or Higher — 0.44; 0.65; 0.63 adverse events

Primary: Number of Differentially Expressed Genes Between Bitten (Case) Versus Unbitten (Control) Skin for Each of the Three Vector Groups — 18; NA; 1; NA number of…

Primary: Successful Infection of Vector Mosquitoes Following Both Direct and Indirect Feeding on the Blood of Infected Participants

Primary: Measurement of Change in Early and Late Innate Immune Responses Using Gene Expression and Flow Cytometry in Participants' Skin — 50; 5 % of total dendritic cells

Primary: Number of Symptomatic Participants Testing Positive for Aedes-borne Virus Infections That Are Laboratory Confirmed or Serologically — 213; 209; 151; 146 Participants

Primary: Frequency of Adverse Events in the CHMI-trans Model — 95; 95; 107; 52 Adverse events

Primary: Incidence of Severity of Treatment Emergent Adverse Events (AEs) by Grade — 7; 8; 10; 8 Participants

Primary: Safety and Reactogenicity (SAEs and AEs) — 45; 53; 22; 37 Number of events

Primary: Malaria Diagnosis Using RealAmp and Microscopy. — 42; 153; 0; 1 Participants

Primary: To Characterize the Infectivity of a New Lot of Plasmodium Falciparum Strain 3D7 Developing Parasitemia Within the Standard WRAIR CHMI Model. — 0; 1; 5; 5 Participants

Primary: P. Vivax Blood Collection — 2 Participants

Primary: Dermatology Life Quality Index (DLQI) Domain Scores — 3; 0; 1; 0 units on a scale

Primary: Confirm Etiologies Among Suspected COVID-19 Cases — 151; 21; 13 Participants

Primary: Percentage of Participants With Demonstrated Seropositivity for Japanese Encephalitis (JE) Neutralizing Antibodies — 98.0; 99.3; 100.0; 100.0 percentage of participants

Primary: Number of Participants Who Experience a Serious Adverse Events (SAEs) 29 Days After the Last Vaccination — 1; 0; 0; 1 Participants

Primary: Infection Success of Vector Mosquitoes — 2; 3 Participants

Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms Within 7 Days of CIS43LS Product Administration — 4; 1; 5; 3 Participants

Primary: Number of Patients With Clinical Phenotype Presenting Also a Sequential Activation of Immune/Infammatory Pathways. — 131 Participants

Primary: Number of Participants With P.Falciparum Blood Stage Infection — 0; 0; 0; 0 Participants

Primary: Number of Participants With Solicited Injection Site Adverse Events — 1; 0 Participants

Primary: Number of Participants With Local and Systemic Adverse Events in Years 1 and 2 — 15; 14; 15; 15 Participants

Primary: Number of Local and Systemic Adverse Events (AEs) to Assess the Safety of the Study Drug — 34; 24; 23; 16 Adverse Events

Primary: Primary: Plasmablast Percentage of Total B Cells at 7 Days Post Vaccine — 1.36; 1.96; 1.69 percent plasmablasts of B cells

Primary: Infection for P. Vivax — 11; 11; 9 days

Primary: Number of Participants Infected With Plasmodium Falciparum (P. Falciparum) by World Health Organisation (WHO) Age Group — 98; 148; 82; 46 Participants

Primary: Occurrence of Solicited Adverse Events Over a 7 Day Follow-up Period After Each Immunization (the Day of the Immunization and 6 Subsequent Days) During the Vaccination…

Primary: Subjects Time to First Clinical Episode of P Falciparum Malaria During the Efficacy Follow-up Period Adjusted for Time at Risk - Intent to Treat (ITT) Population — 107…

Primary: Work Related Tick Bites — 265; 780 tick bites — p=0.004

Primary: Number of Clinical Malaria Episodes Per Year of Follow-up — 0.61; 0.68; 0.64; 0.59 Episodes per PYAR — p=0.8097